Raffles Medical Group Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Raffles Medical Group has been growing earnings at an average annual rate of 12.9%, while the Healthcare industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 9.1% per year. Raffles Medical Group's return on equity is 6%, and it has net margins of 8.7%.
Belangrijke informatie
12.9%
Groei van de winst
12.4%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 15.7% |
| Inkomstengroei | 9.1% |
| Rendement op eigen vermogen | 6.0% |
| Nettomarge | 8.7% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Raffles Medical Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 703 | 61 | 163 | 0 |
| 31 Mar 24 | 706 | 76 | 153 | 0 |
| 31 Dec 23 | 708 | 90 | 142 | 0 |
| 30 Sep 23 | 747 | 117 | 184 | 0 |
| 30 Jun 23 | 786 | 144 | 165 | 0 |
| 31 Mar 23 | 805 | 143 | 137 | 0 |
| 31 Dec 22 | 825 | 143 | 110 | 0 |
| 30 Sep 22 | 808 | 124 | 62 | 0 |
| 30 Jun 22 | 791 | 104 | 13 | 0 |
| 31 Mar 22 | 758 | 94 | 10 | 0 |
| 31 Dec 21 | 725 | 84 | 7 | 0 |
| 30 Sep 21 | 698 | 86 | 7 | 0 |
| 30 Jun 21 | 671 | 88 | 7 | 0 |
| 31 Mar 21 | 619 | 77 | 7 | 0 |
| 31 Dec 20 | 568 | 66 | 7 | 0 |
| 30 Sep 20 | 541 | 60 | 9 | 0 |
| 30 Jun 20 | 508 | 50 | 8 | 0 |
| 31 Mar 20 | 514 | 55 | 9 | 0 |
| 31 Dec 19 | 522 | 60 | 10 | 0 |
| 30 Sep 19 | 514 | 63 | 14 | 0 |
| 30 Jun 19 | 504 | 66 | 16 | 0 |
| 31 Mar 19 | 497 | 69 | 15 | 0 |
| 31 Dec 18 | 489 | 71 | 20 | 0 |
| 30 Sep 18 | 484 | 71 | 18 | 0 |
| 30 Jun 18 | 483 | 71 | 17 | 0 |
| 31 Mar 18 | 483 | 71 | 16 | 0 |
| 31 Dec 17 | 478 | 71 | 15 | 0 |
| 30 Sep 17 | 473 | 70 | 16 | 0 |
| 30 Jun 17 | 473 | 70 | 16 | 0 |
| 31 Mar 17 | 472 | 70 | 16 | 0 |
| 31 Dec 16 | 474 | 70 | 16 | 0 |
| 30 Sep 16 | 470 | 71 | 16 | 0 |
| 30 Jun 16 | 452 | 71 | 15 | 0 |
| 31 Mar 16 | 432 | 70 | 14 | 0 |
| 31 Dec 15 | 411 | 69 | 13 | 0 |
| 30 Sep 15 | 396 | 69 | 11 | 0 |
| 30 Jun 15 | 389 | 68 | 11 | 0 |
| 31 Mar 15 | 382 | 68 | 10 | 0 |
| 31 Dec 14 | 375 | 68 | 10 | 0 |
| 30 Sep 14 | 363 | 89 | 9 | 0 |
| 30 Jun 14 | 353 | 87 | 9 | 0 |
| 31 Mar 14 | 347 | 86 | 9 | 0 |
| 31 Dec 13 | 341 | 85 | 9 | 0 |
Kwaliteitswinsten: 02M1 has high quality earnings.
Groeiende winstmarge: 02M1's current net profit margins (8.7%) are lower than last year (18.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 02M1's earnings have grown by 12.9% per year over the past 5 years.
Versnelling van de groei: 02M1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 02M1 had negative earnings growth (-57.5%) over the past year, making it difficult to compare to the Healthcare industry average (30.9%).
Rendement op eigen vermogen
Hoge ROE: 02M1's Return on Equity (6%) is considered low.